<DOC>
	<DOC>NCT02690337</DOC>
	<brief_summary>This is an open-label study to evaluate the safety, tolerability, and pharmacokinetics of DS-1123a in Japanese subjects with advanced solid tumors.</brief_summary>
	<brief_title>Study of DS-1123a in Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Advanced solid tumor that is refractory to standard treatment, or for which no standard treatment is available. Eastern Cooperative Oncology Group performance status (PS) of 0 or 1. Have any of the following concomitant disease or had the history of having following disease within 6 months before enrollment: • Cardiac failure (NYHA ≥ ClassIII), myocardial infarction, cerebral infarction, unstable angina, arrhythmia requiring treatment, coronaryartery/peripheral artery bypass surgery, cerebrovascular disease, pulmonary thromboembolism, deepvein thrombosis or clinically severe thromboembolic event, or clinically severe pulmonary disease (eg, interstitial pneumonia, pulmonary fibrosis, radiation pneumonia, drug induced pneumonia), Severe or uncontrolled concomitant disease. Clinically active brain metastases defined as symptomatic or requiring treatment.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Advanced solid malignant tumors</keyword>
	<keyword>phase 1</keyword>
	<keyword>oncology</keyword>
	<keyword>refractory</keyword>
	<keyword>no standard treatment</keyword>
</DOC>